尊敬的投资者，
我们诚挚邀请您参加药明康德2022年一季度业绩交流电话会，出席会议请拨打下图电话号码。
中文会议将于北京时间2022年4月26日上午9:00-9:50召开
英文会议将于北京时间2022年4月26日上午8:00-8:50召开
*非白名单用户请通过海报内的链接预先注册参会。
Dear Investors,
WuXi AppTec is pleased to invite you to our 1Q22 Results Webcast. We thank you for your interest and we sincerely hope you will join us.
English Webcast at 8:00-8:50 a.m., April 26, China time (8:00-8:50 p.m., April 25, 2022, EST)
Chinese Webcast at 9:00-9:50 a.m., April 26, China time
*Please sign up in advance for the English webcast through the link on the poster.
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2021年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5700多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,700 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
